Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Drops By 41.5%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 9,600 shares, a decline of 41.5% from the September 15th total of 16,400 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.4% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BPTH shares. Roth Mkm reiterated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a research note on Monday, July 8th. StockNews.com started coverage on shares of Bio-Path in a research report on Monday, October 7th. They set a “sell” rating on the stock.

Bio-Path Trading Down 0.9 %

Shares of BPTH traded down $0.01 during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 243,257 shares, compared to its average volume of 1,267,008. Bio-Path has a twelve month low of $0.85 and a twelve month high of $21.60. The company’s 50-day moving average is $1.11 and its 200-day moving average is $2.02.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings data on Thursday, August 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same period last year, the business earned ($10.60) EPS. On average, sell-side analysts predict that Bio-Path will post -6.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.